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Abstract
Introduction
Patient reported outcomes (PROMs) are increasingly used by clinical teams as quality
indicators when assessing treatment following a diagnosis of head and neck cancer.
Approximately 1/3 of patients report reduced sexual interest or enjoyment following head and
neck cancer therapy. Despite that, there is no intimacy questionnaire developed specifically for
head  and  neck  cancer  patients.  The  objective  of  this  study  was  to  develop  the  first  such
questionnaire, to gain an indication of the relative frequency of individual items and compare
clinical characteristics such as age, stage, treatment, time since treatment, with an established
head and neck cancer (HNC), health-related quality of life (HRQOL) measure (EORTC QLQ-
C30 with the H&N 35 module).
Method
The development of the instrument was based on an exploratory observational study that
included quantitative and qualitative methods. The qualitative element was achieved with
item generation - from the perspective of the literature, patients and carers and a cross-
sectional survey of HCN patients who were alive and disease free. The quantitative element
comprised exploratory and confirmatory factor analysis (EFA and CFA), internal reliability
assessment (Cronbach’s alpha) as well as a correlational analysis.
Results
42 patients were included in the focus groups and a total of 101 patients participated in the
cross-sectional survey. Patients were male and female, in relationships and single, age range
30 to 70 years. All treatment modalities were included.  We demonstrate that the ability to
enjoy a sex life has been adversely affected in about 50% of the sample and that this has significantly
changed from before their cancer in 30% of the patients. The qualitative part of the study resulted
in 22 items covering a range of domains from dry mouth, thick saliva, to loss of sensation
(lips, fingertips), restricted head/neck movement, fatigue and pain. The EFA revealed four
domains (physical, sensation, movement and communication) from 12 of 22 items.
3Cronbach’s alphas ranged from 0.62 to 0.84, and the CFA revealed good fit statistics for
these domains. In terms of the EORTC QLQ-H&N35, the 4 (MHK) domains showed good
levels of association with anticipated domains.
Conclusion
HNC and the associated treatment significantly adversely affects intimacy and sexuality in half
the sample population. The MHK tool may be used to identify specific issues relating to
intimacy in patients with a history of diagnosis and treatment for head and neck cancer. Further
work is essential in order to identify its precise role and to help develop specific interventions.
4Introduction
The diagnosis and treatment for head and neck cancer often have devastating consequences to
patients and their families1. Essential parts of clinical care include the measurement of
symptoms, function and HRQOL, before, during and after treatment.  There are several
assessment  tools  currently  being  used  by  clinical teams,  but  these  tools  do  not  yet  cover
all  the  domains  required  for  a  holistic needs assessment (HNA), which is mandatory in the
UK2.  Following advances in diagnosis and treatment cancer is recognised as behaving as a
chronic disease. Patients may benefit from their partners active involvement in their care.
Recent data found that being married reduced HNC patients’ risk of dying from cancer by 33%
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.  In addition to providing emotional support and helping patients cope with the disease or the
treatment, there is growing recognition that spousal caregivers have their own unique needs
and concerns4. Unmet caregiver support needs have been shown to adversely affect both patient
and caregiver quality of life4. Sexual well-being is an important aspect of patients’
psychological rehabilitation5. The identification of the intimacy problems of patients is an
essential part of relationship needs and this may become more relevant given the rapid rise of
HPV related oropharyngeal cancers6.  Problems with sexuality and intimacy in head and neck
cancer are under reported7,8. Rogers et al (2015)9 concluded that intimacy and sexuality
problems will remain a potential unmet need unless attempts are made to advance the
opportunities for patient screening. Previous work has highlighted shortcomings in the
identification of problems with intimacy and sexuality in patients treated for head and neck
cancer10,11,12.  The  aim  of  this  work  was  to  develop  an  intimacy  questionnaire  applied
specifically to HNC patients.
Materials and method
For this work we followed and developed further the methodology that was previously
published13,14. We started with the following hypothesis and objective:
Hypothesis: Using a specifically developed tool in clinical practice will help to identify
patient intimacy and sexual dysfunction concerns, improve consultations between
professionals and patients so that their concerns are highlighted and addressed.
Specific objective: To develop an intimacy tool specific to HNC. The development of the
instrument was based on an exploratory observational study that included quantitative and
qualitative methods.
5This was achieved with two phases.
Phase 1:  Item generation - from the perspective of the literature, clinical specialists, patients
and carers.
Phase 2: A cross-sectional survey of HNC patients who were alive and disease free. The aim
of phase 1 was to provide a working draft of intimacy issues that were relevant to HNC
patients. The aim of the cross-sectional survey (Phase 2) was to gain an indication of the
relative frequency of individual items and compare clinical characteristics such as age, stage,
treatment, time since treatment, with an established Head and Neck cancer HRQOL measure
(EORTC C30 with the H&N 35 module). During phase 1 (item generation phase) the
following steps were undertaken:
I) A structured literature review of HRQOL questionnaires specific to head and neck
cancer and general intimacy and sexual dysfunction tools was completed and
published11.
II) Patients were recruited prospectively from the Head and Neck clinics of the
relevant hospitals and participated in 4 focus groups of 8-12 participants. All
discussions were audio recorded to ensure quality.
III) National bodies – British Association of Oral and Maxillofacial Surgeons
(BAOMS) and the British Association of Head and Neck Oncologists
(BAHNO)were contacted to explain the background of the tool and asked to
comment on the draft resulting from step III.
At the end of steps I and II, a preliminary intimacy tool was constructed highlighting the most
relevant concerns patients might wish to raise in out-patient clinics. There are 2 parts to the
tool. First, any existing intimacy and or sexual function issues, if present, are identified.
Second, specific items which impact on intimacy after HNC and/or treatment for HNC.
The items on this preliminary tool were shown (in semi-structured interview format) to
patients in 4 focus groups (step III), to identify which items had the greatest impact on daily
living from the patients' point of view and the acceptability of language being used. Focus
groups and semi-structured interviews were analysed concurrently with data collection to
identify key themes and sub-themes by content analysis.  After transcribing the interviews,
relevant phrases/expressions were obtained for each of the assessed items. This was followed
6by an initial qualitative reduction of the identified sentences, in which expressions that may
be considered inappropriate, ambiguous or redundant were excluded. During phase 2 we
conducted a prospective cross-sectional survey of HNC patients. Disease free patients with a
history of HNC in the last 11 years were included. Patients with metastatic disease or with
cancer at other sites were excluded from the study. Patient were identified in the head and
neck clinics. Interested patients were given a study information pack. The information pack
contained the HRQOL measure (EORTC 30 with the H&N 35 module (4)), appropriate
consent, GP contact documentation, details about the study and the preliminary tool that was
constructed in Phase 1. Patients were asked to identify items they think should be included
and any items they think should be removed or could add any items they think were missing.
Demographic and clinical characteristics such as age, stage, treatment, time since treatment
were accessed via clinic records. For phase 1 we recruited 8-12 patients per focus group and
for phase 2 we aimed for 100 patients. These figures are p r a g m a t i c a n d based on a
literature review and retrospective audit of the experience obtained during the development
of the other tools in oncology15,16,17. All data were entered into SPSS (Version 25.0, IBM
SPSS Statistics) after the removal of all personal identifiers. Additional analyses were also
carried out with RStudio using the lavaan library package. Qualitative data was audio-
recorded and transcribed verbatim. Anonymous identity codes were used to assure the
identity of participants was not revealed. This work was approved by; Calderdale and
Huddersfield Research and Ethics Committee, the Health Research Authority Ethics
Committee and Leeds Central Ethics Committee.
Instruments
Patients completed the EORTC QLQ-C30 as well as the associated Head and Neck Cancer
module (H&N35). The EORTC QLQ-C30 comprises five functional scales (physical
functioning, role functioning, emotional functioning, cognitive functioning and social
functioning), and eight symptoms scales (fatigue, nausea and vomiting, pain, dyspnoea,
insomnia, appetite loss, constipation, diarrhoea). In addition to this there is one financial
difficulties scale, and a global health status or quality of life scale (GHS). With the exception
of the latter, all responses are scored on a 4-point Likert scale (Not at all, A little, Quite a bit,
Very much). The GHS is scored on a 7-point numeric rating scale with 2 anchors: “Very poor”
and “Excellent”. The H&N35 is scored in the same way as the EORTC QLQ-C30 functional
7scales and consists of 15 scales covering issues particular to head and neck cancer, such as
swallowing, sense problems, speech problems, dry mouth and sticky saliva. Raw scores on
these instruments are converted to a 0-100 scale. For the EORTC QLQ-C30 functioning scales
and GHS, higher scores indicate better functioning, whereas higher scores on the symptom
scales and H&N35 indicate worse symptoms1.
In  the  cross-sectional  survey  patients  completed  the  EORTC  QOL-C30  with  the  H&N  35
module in addition to the MHK tool that derived in Phase 1 of the study. This tool included
some  general  questions  relating  to  intimacy  and  sexuality,  a  list  of  treatment  related
complications applicable to both sexes followed by sections that are completed by male or
female patients only. The four response categories on the MHK (“Not at all”, “A little”, “Quite
a bit”, “A lot”) were scored on a scale from 1 to 4.
Statistics
Descriptive statistics were derived for the sample describing the patients’ basic clinical details.
The EORTC QLQ-C30 and H&N35 module were converted to scale scores using the published
algorithms (EORTC, 2001).
Factor analysis
An exploratory factor analysis was undertaken using principal components analysis (PCA).
This was applied with a varimax rotation (assuming orthogonality or no correlation between
the factors) to determine the factors structure of the MHK. Factor loadings were assessed
against a criterion of >0.4. Scree plot, eigen values >1 (Kaiser’s criterion), and percentage
variance explained were used to determine the optimal number of factors present. Cronbach’s
alpha was used to assess the internal reliability of the putative factors.
Validation
Confirmatory factor analysis was applied to further assess the factor structure of the MHK
instrument. Model fit was evaluated using the root mean square error of approximation
(RMSEA<0.08), and comparative fit index (CFI>0.90).
1
 EORTC QLQ-C30 Scoring Manual. Third Edition. 2001. www.eortc.be
8Pearson’s correlations were used to determine degree of association between the EORTC QLQ-
C30, H&N35 and the MHK.
All analyses were undertaken using IBM SPSS Statistics version 25 and AMOS version 25
(IBM).
Results
Results for the initial MHK questionnaire are shown in Table 1 and 4.   Forty-two patients were
included in the focus groups. Each session included one hour of open discussion, led by the
group and facilitated by one of the authors (JH). The groups changed the language of the
questionnaire items, for example question 1 b, one group wished the language to be "compared
to  your  sex  life  at  its  best",  to  another  group wishing  to  say,  "pre,  your  cancer"  and  it  was
agreed by all patients to use "compared to your sex life previously". For the desire for Intimacy
Questions: the scale was agreed by the focus groups. The tool is now in version 10, this is with
the impact of every group and feedback, as well as the final reliability and validity of relevant
questions.
A total of 101 patients participated in the cross-sectional study. Table 2 shows a breakdown of
the patient demographic details. As may be seen, just under 37% of the sample were female,
average age was 62 years (range: 35.5 to 117.8 years). The majority of patients had surgery
alone or with adjuvant treatment.
Outcome measures – EORTC QLQ-C30 and EORTC QLQ-H&N35
Complete data were available for between 84 to 89 patients (not all patients completed all of
the questions) (Table 3). In general, patients reported relatively good levels of functioning and
quality of life compared to reference values for patients with head and neck cancers, although
slightly worse in terms of symptoms, such as fatigue and pain. Similarly, cancer-specific
symptomatology was also broadly in line with reference values, although this sample of
patients reported a greater degree of impairment with symptoms such as dry mouth and sticky
saliva, as well as a greater use of painkillers and nutritional supplements.2
2
 EORTC QLQ-C30 Reference Values. 2008 (pp. 118 and 310)
9Outcome measures – MHK
Table 1 shows the impact patients feel their cancer has had on their ability to enjoy a sex life.
As can be seen from Q1 and Q2, the ability to enjoy a sex life has been impacted in about 50% of the
sample (Q1), and this has significantly changed from previously in 30% of the patients (Q2). 19% report
they did not want to engage in sex (Q3), the remaining 81% reporting they did from a little to very
much.
Table 4 as may be seen, symptoms such as dry mouth, breath smelling, thick saliva, as well as
loss of confidence and tiredness or fatigue were where patients reported the greatest level of
problems. Patients reported fewest problems in areas such as the use of a feeding tube or an
airway stoma, reflux symptoms, breathing difficulties, as well as loss of fingertip sensation and
thrush or oral candida.
Factor analysis
Figure 1 shows the final factor solution for the MHK questionnaire. Items with factor loadings
<0.4 were removed from the analysis: this led to the removal of 10 items, some of which (e.g.
breathing difficulties, feeding tube, airway stoma) had previously been identified as having
low levels of patient endorsement. The remaining 12 items accounted for 68.5% of the total
variance and comprised 4 factors: “Physical” (4 items), “Sensation” (2 items), “Movement”
(3) and “Communication” (3). Cronbach’s alphas for each of these factors were, respectively:
0.71, 0.84, 0.62 and 0.73, suggesting good internal reliability for the 4 factors, although
“Movement” was slightly lower than the 0.70 criterion.
Validation
The results of the confirmatory factor analysis showed RMSEA of 0.082 (90% confidence
intervals, CI: 0.044 to 0.116), and CFI of 0.908. Both indices suggesting good model fit for the
4-factor structure.
The Communication and Movement domains from the MHK showed a significant negative
association  with  the  Role  Functioning  and  GHS  /  QoL  domains  on  the  EORTC  QLQ-C30
(Table 5), suggesting that impairments in these domains has a detrimental effect on patients’
quality of life and ability to undertake usual daily activities. The Physical domain on the MHK
showed significant associations with Physical, Role, Social and Cognitive Functioning, as well
with both Fatigue and Pain domains on the EORTC QLQ-C30.
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In terms of the EORTC QLQ-H&N35, the MHK domains showed good levels of association
with anticipated domains. For instance, the Communication domain showed good associations
with the Speech, and Social Contact domains on the QLQ-H&N35. Similarly, the Movement
factor  showed  a  good  degree  of  association  with  the  Opening  Mouth  domain  on  the  QLQ-
H&N35. The Physical, Sensation, Communication and Movement domains were associated
with the Sexuality domain on the QLQ-H&N35.
Discussion
The work gives a detailed account of the cross-sectional study. The details and the contribution
of the focus groups are beyond the scope of this paper. It is however, important to recognise
their  part  in  developing  this  tool  and  its  acceptability  of  use,  both  for  them  and  what  they
believe their head and neck team can do to help. The intimacy questions came from one of the
authors experience in providing PST to head and neck patients over 2 years and patients
concerns that have simple practical solutions that the general medical team could approach and
help with. The focus groups ordered and listed what they believed was an impact on their
intimacy. The results show that sexual function and intimacy are affected by head and neck
cancer and/or its treatment. Patients may use this tool to highlight areas that can be improved.
The principle areas of concern are not specific to psychosexual therapy and could benefit from
relatively low-level education in the areas of intimacy and sexuality. This can address both
why things have changed and how things could be improved.
The results from the cross-sectional study revealed a 4-factoror domain structure for the MHK.
This suggests use in practice of the 4 summed domains, however the additional 10 questions
are crucial to delineate the precise problem in clinical practice. One potential limitation of the
study is the relatively low numbers for the factor analyses. Additional research with larger or
pooled samples is required to support the factor structure of the MHK. Useful qualitative data
emerging from this process included the observations that intimacy and sexual function issues
are not exclusive to those in active sexual relationships. Singletons have been poorly served by
previous research.3 This study highlighted that there are problems with intimacy and sexual
function in people who have had HNC whether in a relationship or not and this needs to be
considered  by  the  clinical  teams supporting  this  group of  patients.  In  the  UK a  (HNA) is  a
mandatory part of the patients’ recovery package. Patients who indicate from their HNA an
11
issue with intimacy or sexual function now have a more detailed tool which will highlight more
specific areas of concern that can be addressed.
Whilst our aspirations for this tool are to highlight intimacy and sexual function issues for HNC
patients the MHK tool only “opens the door” for discussion of these issues. It does not direct
the clinician towards solutions but it does allow patients to communicate their intimacy
problems. This is very much in keeping with modern clinical care, embracing the issues around
survivorship in cancer. What would be helpful to both patients and clinical teams is to have
accurate patient sexual health education information12,  services to which the patients can be
referred such as hospital based psychosexual therapy services or community “Relate”
psychosexual services. It is also important to understand that psychosexual therapists don’t
necessarily have any specialist cancer knowledge and awareness of its impact on intimacy or
sexual function. This, therefore, is not an issue simply to be referred out. What is important to
understand is that each of the desire for intimacy questions have relatively simple interventions
that could improve the patients’ situation that can be delivered by the clinical head and neck
team. Questionnaire 1 was used in the cross-sectional study. As a consequence of both
quantitative and qualitive assessment, this was modified and the final questionnaire
(Questionnaire 2) was produced.
Conclusion.
Further research in order to evaluate the MHK tool is essential. A larger patient cohort, a
longitudinal  approach,  qualitative  input,  and  a  link  to  possible  interventions,  would  each
improve  our  understanding  of  the  intimacy issues  faced  by  head and neck cancer  patients
and suggest possible steps to improve their situation.
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Questionnaire 1: This is the initial MHK questionnaire that was included in the cross-
sectional study
[TYPE THE SENDER COMPANY ADDRESS]
[Pick the date]
Initials:
D.O.B:
For the purpose of this questionnaire we define sexual activity as any stimulation of the mind or body for pleasurable
erotic stimulation. This includes penetrative intercourse, masturbation, sexual fantasies and any related or similar erotic
activity. Please note we have deliberately included questions applicable to both males and females as responses relevant
to your partner may have a direct impact on you.
Since your cancer diagnosis please indicate which single answer most applies to you from the following questions.
1(a) Do you think that your cancer has impacted your ability to enjoy a sex life? Yes Ƒ No
Ƒ
1(b) Compared to your sex life previously, how much has this impacted on how much you
enjoy it now?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
2. How often have you thought about sex with real interest or desire in the last week?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
3(a) How often do you want to engage in any form of sexual activity?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
3(b) Is this different to before your diagnosis? Yes Ƒ No Ƒ
3(c) Is this different from your partner(s)? Yes Ƒ   No Ƒ   Not sure Ƒ
3 (d) Can you identify a reason why this may be different………………………………….
4(a) Do you feel that since your cancer diagnosis that your relationship with your partner has
changed? (ie more of a carer than a partner)
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
 4(b) Would you like help/advice to discover a non-sexual and close relationship back with
your partner,
15
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ4(c)
Would you like help/advice to discover your sexual relationship back with your partner
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
For females:
1(a) Do you vaginally lubricate during sexual intercourse?
Not at all    Ƒ Sometimes   Ƒ Often   Ƒ Always    Ƒ
1(b) Has this changed since your cancer treatment?
Yes    Ƒ No Ƒ Unsure   Ƒ
If Yes, do you have a reason why?..............................................................
2(a) How often do you become aroused either mentally or physically and then lose interest?
Daily Ƒ     Weekly Ƒ     Monthly Ƒ     Other (please state)……..
2(b) Has this changed since your diagnosis of cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) worse    Ƒ
2(c) Has this changed since your treatment for cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) worse    Ƒ
3(a) Do you experience difficulty to achieve an orgasm?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
3(b) Is this different since your cancer treatment?
Yes    Ƒ No Ƒ Unsure   Ƒ
3(c) Is this important to you?
Yes Ƒ                            No Ƒ             Unsure   Ƒ
4. Are you: 1) Menstruating     Ƒ        2) Pre-menopausal   Ƒ         3) Menopausal Ƒ
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For males:
1, How difficult is it for you to achieve a full or partial erection?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
a. Was this sufficient for penetrative sex?    Yes Ƒ   No Ƒ
b. Is this different to before your cancer? Yes Ƒ   No Ƒ
c. Is this different to after your cancer treatment? Yes Ƒ   No Ƒ
2(a) Do you experience difficulty in achieving an orgasm?
Yes    Ƒ No   Ƒ Unsure   Ƒ
2(b) Is this different since your cancer treatment?
Yes    Ƒ No Ƒ Unsure   Ƒ
If Yes, do you have a reason why?....................................................
2(c) Is this important to you?
Yes Ƒ                            No Ƒ             Unsure   Ƒ
2(d) Do you experience erections on waking in the morning?
 Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
3(a) How often do you become aroused either mentally or physically and then lose interest?
Daily Ƒ      Weekly Ƒ      Monthly Ƒ     Other (please state)……..
3(b) Has this changed since your diagnosis of cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) Worse    Ƒ
3(c) Has this changed since your treatment for cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) Worse    Ƒ
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Do any of the following affect your desire for intimacy (please tick):
Dry mouth Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Breath smelling Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Thick saliva Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Breathing difficulties Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Restricted tongue movement Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of feeling in your lips Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of control of lip suction Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of feeling in your tongue Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Feeding tube Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Airway stoma Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of confidence Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Anxiety Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Reflux             Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Restricted neck movement Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Restricted head movement Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Scars from surgery Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of sensation in fingertips Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
due to chemotherapy
Communication/speech difficulties   Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Tiredness/exhaustion/fatigue  Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Pain Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Thrush/oral candida Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
18
Questionnaire 2: The final MHK questionnaire following the cross-sectional study
[TYPE THE SENDER COMPANY ADDRESS]
[Pick the date]
Initials:
D.O.B:
For the purpose of this questionnaire we define sexual activity as any stimulation of the mind or body for pleasurable
erotic stimulation. This includes penetrative intercourse, masturbation, sexual fantasies and any related or similar erotic
activity. Please note we have deliberately included questions applicable to both males and females as responses relevant
to your partner may have a direct impact on you.
Since your cancer diagnosis please indicate which single answer most applies to you from the following questions.
1(a) Do you think that your cancer has impacted your ability to enjoy a sex life? Yes Ƒ No
Ƒ
1(b) Compared to your sex life previously, how much has this impacted on how much you
enjoy it now?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
2. How often have you thought about sex with real interest or desire in the last week?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
3(a) How often do you want to engage in any form of sexual activity?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
3(b) Is this different to before your diagnosis? Yes Ƒ No Ƒ
3(c) Is this different from your partner(s)? Yes Ƒ   No Ƒ   Not sure Ƒ
3 (d) Can you identify a reason why this may be different………………………………….
4(a) Do you feel that since your cancer diagnosis that your relationship with your partner has
changed? (ie more of a carer than a partner)
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
 4(b) Would you like help/advice to discover a non-sexual and close relationship back with
your partner,
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Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ4(c)
Would you like help/advice to discover your sexual relationship back with your partner
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
Do any of the following affect your desire for intimacy (please tick):
Dry mouth Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Breath smelling Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Thick saliva Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Breathing difficulties Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Restricted tongue movement Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of feeling in your lips Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of control of lip suction Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of feeling in your tongue Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Feeding tube Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Airway stoma Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of confidence Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Anxiety Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Reflux             Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Restricted neck movement Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Restricted head movement Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Scars from surgery Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Loss of sensation in fingertips Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
due to chemotherapy
Communication/speech difficulties   Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Tiredness/exhaustion/fatigue  Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Pain Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
Thrush/oral candida Not at all Ƒ A little Ƒ  Quite a bit Ƒ  A lot Ƒ
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For females:
1(a) Do you vaginally lubricate during sexual intercourse?
Not at all    Ƒ Sometimes   Ƒ Often   Ƒ Always    Ƒ
1(b) Has this changed since your cancer treatment?
Yes    Ƒ No Ƒ Unsure   Ƒ
If Yes, do you have a reason why?..............................................................
2(a) How often do you become aroused either mentally or physically and then lose interest?
Daily Ƒ     Weekly Ƒ     Monthly Ƒ     Other (please state)……..
2(b) Has this changed since your diagnosis of cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) worse    Ƒ
2(c) Has this changed since your treatment for cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) worse    Ƒ
3. Are you: 1) Menstruating     Ƒ        2) Pre-menopausal   Ƒ         3) Menopausal Ƒ
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For males:
1 How difficult is it for you to achieve a full or partial erection?
Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
a. Was this sufficient for penetrative sex?    Yes Ƒ   No Ƒ
b. Is this different to before your cancer? Yes Ƒ   No Ƒ
c. Is this different to after your cancer treatment? Yes Ƒ   No Ƒ
2 Do you experience erections on waking in the morning?
 Not at all    Ƒ A little   Ƒ Quite a bit   Ƒ Very much    Ƒ
3(a) How often do you become aroused either mentally or physically and then lose interest?
Daily Ƒ      Weekly Ƒ      Monthly Ƒ     Other (please state)……..
3(b) Has this changed since your diagnosis of cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) Worse    Ƒ
3(c) Has this changed since your treatment for cancer?
Yes    Ƒ No Ƒ Unsure   Ƒ
If changed is it:   1) Better Ƒ   2) Worse    Ƒ
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Table 1- indicating the impact patients feel their cancer has had on their ability to enjoy a sex
life.
X1aEnjoy sex life
Frequency Percent Valid
Percent
Valid Not at all 46 45.5 51.1
Quite a bit 1 1 1.1
Very much 43 42.6 47.8
Total 90 89.1 100
Missing 11 10.9
Total 101 100
X1b Impact sex life
Frequency Percent Valid
Percent
Valid Not at all 26 25.7 30.2
A little 32 31.7 37.2
Quite a bit 18 17.8 20.9
Very much 10 9.9 11.6
Total 86 85.1 100
Missing 15 14.9
Total 101 100
X2Sexual desire
Frequency Percent Valid
Percent
Valid Not at all 24 23.8 27.9
A little 31 30.7 36
Quite a bit 26 25.7 30.2
Very much 5 5 5.8
Total 86 85.1 100
Missing 15 14.9
Total 101 100
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X3a Sexual activity
Frequency Percent Valid
Percent
Valid Not at all 16 15.8 19
A little 37 36.6 44
Quite a bit 26 25.7 31
Very much 5 5 6
Total 84 83.2 100
Missing 17 16.8
Total 101 100
3bSex life (change)
Frequency Percent Valid
Percent
Valid 17 16.8 16.8
No 55 54.5 54.5
Yes 29 28.7 28.7
Total 101 100 100
3cPartner sex life
Frequency Percent Valid
Percent
Valid 26 25.7 25.7
No 26 25.7 25.7
Not Sure 35 34.7 34.7
Yes 14 13.9 13.9
Total 101 100 100
X4a Relationship change
Frequency Percent Valid
Percent
Valid Not at all 34 33.7 41.5
A little 29 28.7 35.4
Quite a bit 17 16.8 20.7
Very much 2 2 2.4
Total 82 81.2 100
Missing 99 19 18.8
Total 101 100
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Table 2: Demographical information of patients included in the cross-sectional study
Count Percent
Sex
Male 64 63.4
Female 37 36.6
Mean Min Max
Age Male 62.2 40.39 117.83
Female 62.3 34.52 85.82
Overall 62.3 34.52 117.83
Clinical
Diagnosis Oral cavity all
sites
56
Oropharynx
14
Larynx 12
Head and
Neck (site
not specified
but included
lip, malignant
parotid
disease,
hypopharynx
and
nasopharynx)
19
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Treatment modality
Surgery: 22
Surgery with adjuvant radiotherapy or
Chemo-radiotherapy:                             34
Radical radiotherapy: 13
Primary chemo-radiotherapy: 22
Not recorded 10
T_Staging  T0 3 3
T1 21 20.8
T2 40 39.6
T3 10 9.9
T4 13 12.9
TX 3 3
Not recorded 11 10.9
N_Staging
N1 9 8.9
N2 26 25.7
N2A 8 7.9
N2C 6 5.9
NO 41 40.6
Not recorded 11 10.9
M_Staging
M0 100
MX 1
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Table 3: EORTC responses of patients in the cross-sectional study
EORTC QLQ-C30 Mean
Std.
Deviation        N      Min Max
Physical Functioning PF 83.8 19.76 87 13.33 100
Role Functioning RF 75.5 30.37 89 0 100
Social Functioning SF 73.9 30.30 88 0 100
Cognitive Functioning CF 80.9 21.52 88 0 100
Emotional Functioning EF 74.3 23.85 88 0 100
Global Health Status
(Quality of Life) QL 66.5 21.76 89 8.33 100
Fatigue FA 31.8 25.93 87 0 100
Pain PA 31.8 25.93 87 0 100
Nausea & Vomiting NV 7.8 13.12 88 0 66.67
Dyspnoea DY 16.1 28.03 89 0 100
Sleeplessness SL 31.8 30.88 87 0 100
Appetite AP 25.0 32.06 88 0 100
Constipation CO 20.1 28.38 88 0 100
Diarrhoea DI 7.1 19.12 89 0 100
Finance FI 18.6 33.47 88 0 100
H&N35
Pain HNPA 30.1 25.87 87 0 100
Swallowing HNSW 22.8 24.36 87 0 100
Senses problems HNSE 20.1 25.29 88 0 100
Speech problems HNSP 22.7 24.22 86 0 100
Trouble with social eating HNSO 29.6 29.95 85 0 100
Trouble social contact HNSC 9.6 14.69 83 0 66.67
Less sexuality HNSX 24.6 33.68 84 0 100
Teeth HNTE 19.5 28.34 89 0 100
Opening mouth HNOM 22.1 30.13 89 0 100
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Dry mouth HNDR 49.4 37.98 89 0 100
Sticky saliva HNSS 37.5 38.21 89 0 100
Coughing HNCO 29.2 30.49 89 0 100
Felt ill HNFI 16.9 24.68 89 0 100
Pain killers HNPK 65.1 47.94 86 0 100
Nutritional supplements HNNU 43.0 49.80 86 0 100
Feeding tube HNFE 17.6 38.35 85 0 100
Weight loss HNWL 34.1 47.69 85 0 100
Weight gain HNWG 17.6 38.35 85 0 100
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Table 4: Responses to the initial version of the MHK questionnaire
Count %
Items / Response Category Not at all A little Quite a bit A lot Total Missing Not at all A little Quite a bit A lot Total Missing
Dry Mouth 38 18 12 21 89 12 37.6 17.8 11.9 20.8 88.1 11.9
Breath Smelling 62 14 9 3 88 13 61.4 13.9 8.9 3.0 87.1 12.9
Thick Saliva 51 16 11 10 88 13 50.5 15.8 10.9 9.9 87.1 12.9
Breathing Difficulties 70 8 6 3 87 14 69.3 7.9 5.9 3.0 86.1 13.9
Restricted tongue movement 57 17 8 5 87 14 56.4 16.8 7.9 5.0 86.1 13.9
Loss of feeling (lips) 71 10 2 5 88 13 70.3 9.9 2.0 5.0 87.1 12.9
Loss of control (lip suction) 68 12 3 5 88 13 67.3 11.9 3.0 5.0 87.1 12.9
Loss of feeling (tongue) 61 12 8 7 88 13 60.4 11.9 7.9 6.9 87.1 12.9
Feeding tube 75 4 2 5 86 15 74.3 4.0 2.0 5.0 85.1 14.9
Airway stoma 80 1 - 1 82 19 79.2 1.0 0.0 1.0 81.2 18.8
Loss of confidence 50 20 14 4 88 13 49.5 19.8 13.9 4.0 87.1 12.9
Anxiety 49 23 9 5 86 15 48.5 22.8 8.9 5.0 85.1 14.9
Reflux 76 8 3 1 88 13 75.2 7.9 3.0 1.0 87.1 12.9
Restricted neck movement 59 21 7 1 88 13 58.4 20.8 6.9 1.0 87.1 12.9
Restricted head movement 70 16 2 - 88 13 69.3 15.8 2.0 0.0 87.1 12.9
Scars from surgery 68 13 5 2 88 13 67.3 12.9 5.0 2.0 87.1 12.9
Loss of sensation (fingertips) 83 3 - - 86 15 82.2 3.0 0.0 0.0 85.1 14.9
Communication (speech difficulties) 67 10 9 2 88 13 66.3 9.9 8.9 2.0 87.1 12.9
Tiredness (exhaustion / fatigue) 41 27 16 5 89 12 40.6 26.7 15.8 5.0 88.1 11.9
Pain 55 24 7 3 89 12 54.5 23.8 6.9 3.0 88.1 11.9
Thrush (oral candida) 74 8 4 2 88 13 73.3 7.9 4.0 2.0 87.1 12.9
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Figure 1: This includes details of the final factor solution for the MHK questionnaire.
Component
Item /  Factors Communication Physical Sensation Movement
Dry mouth - 0.528 - -
Breath smelling - 0.786 - -
Thick saliva - 0.791 - -
Restricted tongue movement 0.833 - - -
Loss of feeling (lips) - - 0.881 -
Loss of control (lip suction) - - 0.850 -
Loss of feeling (tongue) 0.740 - - -
Loss of confidence - 0.433 - 0.566
Restricted neck movement - - - 0.702
Restricted head movement - - - 0.801
Communication speech difficulties 0.660 - -
Tiredness (exhaustion/ fatigue) 0.402 0.544 - -
Extraction Method: Principal Component Analysis.
Rotation Method: Varimaxwith Kaiser Normalization.
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Table 5: Associations between the initial MHK and EORTC QLQ-C30 and H&N Module
Domains PF RF SF CF EF QL FA PA NV DY SL AP CO DI FI
Communication -0.093 -.311** -0.201 -0.078 -0.043 -.237* 0.17 0.17 -0.017 0.069 -0.033 0.044 0.137 -0.107 0.093
Physical -.305** -.405** -.298** -.329** -0.084 -.395** .387** .387** 0.11 0.141 0.078 0.201 .220* .240* 0.14
Sensation -0.134 -.272* -.363** -0.18 -0.004 -.217* .275* .275* 0.131 0.096 0.112 0.074 0.188 .331** 0.143
Movement -0.15 -.222* -0.177 -.224* -.213* -.294** .273* .273* .306** .337** .286** .227* .284** .214* .240*
Domains HNPA HNSW HNSE HNSP HNSO HNSC HNSX HNTE HNOM HNDR HNSS HNCO HNFI HNPK HNNU HNFE HNWL HNWG
Communication .251*  .390**  .257*  .399**  .355**  .299**  .275* -0.001 0.196 0.102 0.149 0.176 0.057 .221*  .292**  .292** 0.009 0.031
Physical .280**  .306**  .441**  .300**  .425**  .229*  .369** 0.015 0.161 .294**  .345**  .238* 0.147 0.176 .338**  .250* 0.104 0.101
Sensation .306** 0.184 .277** 0.166 0.213 .253*  .240* -0.122 0.166 0.155 0.075 0.021 -0.001 .229* 0.112 0.023 0.032 -0.06
Movement .390** 0.167 .215* 0.152 .225*  .273*  .361** -0.001 .336** 0.201 0.111 0.104 .251*  .253* 0.207 -0.016 0.106 -0.036
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
